References
- [1] Yamaguchi H, Hori M, Suzuki O, et al. Clinical Significance of the Apparent Diffusion Coefficient Ratio in Prostate Cancer Treatment with Intensity-modulated Radiotherapy Anticancer Res. 2016;36(12):6551-6556.
- [2] Qi WX, Zhang Q, Li P, et al. The predictive role of ADC values in prostate cancer patients treated with carbon-ion radiotherapy: initial clinical experience at Shanghai Proton and Heavy Ion Center (SPHIC). J Cancer Res Clin Oncol. 2016;142(6):1361-1367.
- [3] Casares-Magaz O, van der Heide UA, Rørvik J, et al. A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps. Radiother Oncol. 2016;119(1):111-116.
- [4] Iannelli G, Caivano R, Rago L, et al. Diffusion-weighted magnetic resonance imaging in patients with prostate cancer treated with radiotherapy. Tumori. 2016;102(1):71-76.
- [5] Decker G, Mürtz P, Gieseke J, et al. Intensity-modulated radiotherapy of the prostate: dynamic ADC monitoring by DWI at 3.0 T. Radiother Oncol. 2014;113(1):115-120.
- [6] Morgan VA, Riches SF, Giles S, et al. Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am J Roentgenol. 2012;198(3):596-602.
- [7] Park SY, Kim CK, Park BK, et al. Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):749-755.
- [8] Song I, Kim CK, Park BK, Park W. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol. 2010;194(6):477-482.